Marina Presents Data on Target Knockdown in Malignant Ascites Model | GenomeWeb

Marina Biotech this week released data showing that its proprietary RNAi molecules delivered with an in-house liposome delivery vehicle could be used to knock down target mRNA levels in an orthotopic model of malignant ascites.

“Malignant ascites, also known as malignancy-related ascites, is a condition in which fluid collects in the abdomen as a result of cancer,” commonly ovarian and gastrointestinal cancers, according to the company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.